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Haematopoietic progenitor cells (HPC) are attracted by experimental gliomas in vivo.This attraction is further
enhanced by irradiation or hypoxic preconditioning of the glioma cells. Adhesive interactions might be critical
to the preferential accumulation of HPCwithin the glioma tissue.Here, we studied the interactions of HPCwith
endothelial cells. Exposure of human cerebral endothelial cells (SV-HCEC), human microvascular endothelial
cells (HMEC) and brain tumour endothelial cells derived from human glioblastomas (BTEC) to supernatants
of glioma cells and primary glioma cells (SN-G) induced the expression of E-selectin (CD62E).CD62E expression
was further enhancedwhen the glioma cells had been exposed to irradiation or hypoxia prior to the collection of
supernatants, as well as by irradiation or exposure to hypoxia of the endothelial cells. Vascular cell adhesion
molecule 1 (VCAM-1) was constitutively expressed on SV-HCEC,HMEC and BTEC, but was not modulated by
SN-G, irradiation or hypoxia. Transendothelial HPC migration was enhanced after CD62E induction in vitro.
Neutralizing antibodies to CD62E strongly reduced the homing of lin^Sca-1+c-kit+ cells to orthotopic SMA-560
gliomas in vivo.Tissuemicroarray sampling normal brain tissue and astrocytomas of WHOgrades II^IVrevealed
a selective expression of CD62E on endothelial cells of tumour vessels. SN-G-induced CD62E expression on
endothelial cells in vitro required transforming growth factor (TGF)-b signalling in glioma cells and vascular
endothelial growth factor (VEGF)/VEGF receptor 2 (VEGF-R2) signalling in endothelial cells. Further, we
observed a nuclear factor kappa B-dependent activation of the CD62E promoter peaking at 12 h after VEGF-
R2 activation by glioma-derived VEGF. Taken together, we identify glioma cell-induced CD62E expression on
endothelial cells as one mediator of the glioma tropism of HPC.
Keywords: brain tumour; haematopoietic progenitor cells; hypoxia; irradiation; vascular endothelial growth factor,
CD62E
Abbreviations: BTEC = brain tumour endothelial cells isolated from human glioblastoma tissue; CD = cluster
of differentiation; CD62E = E-selectin; CD62P = platelet selectin; CXCL12 = CXC chemokine ligand 12;
DAPI = 40,6 -diamidino-2-phenylindole; ELISA = Enzyme-linked immunosorbent assay; FCS = foetal calf serum;
G-CSF = granulocyte colony stimulating factor; HIF = hypoxia-inducible factor; HMEC = human microvascular endothelial
cells, HPC = haematopoietic progenitor and stem cells; IL = interleukin; LSK = lin^Sca-1+c-kit+; NFkB = nuclear factor
kappa B; NT = no treatment; pVEGF-R2 = phosphorylated VEGF-R2; sKitL = soluble Kit ligand; sCD62E = soluble E-selectin;
SCF = stem cell factor; SDF = stromal cell-derived factor; SN-G = supernatant of glioma cell lines LNT-229, LN-308 and
primary glioma culturesT113, T132, T159; SN-Gp = supernatant of LNT-229 puro cells; SN-GpSD-208 = supernatant of
SD-208-treated LNT-229 puro cells; SN-G-siTGF-b = supernatant of LNT-229 siTGF-b1,2 cells stably expressing shRNAs
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targetingTGF-b1 and TGF-b2; SN-FHAS = supernatant of SV-FHAS cells, SN-GRT = supernatant of irradiated glioma cells,
SN-GHO = supernatant of hypoxic glioma cells; SFM = serum-free medium; SFI = specific fluorescence index;
SV-HCEC = human cerebral endothelial cells; SV-FHAS = human astrocytic cell line; TGF-b = transforming growth factor-b;
TNF-a= tumour necrosis factor-a; VCAM = vascular cell adhesion molecule; VEGF = vascular endothelial growth factor;
VEGF-R = VEGF receptor
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Introduction
Intracerebral experimental gliomas attract intravenously
injected CD34+ haematopoietic progenitor and stem cells
(HPC). The underlying molecular pathways leading to the
glioma tropism of HPC involve a transforming growth
factor (TGF)-b-dependent signalling cascade regulating the
release of stromal cell-derived factor (SDF)-1a/CXC
chemokine ligand 12 (CXCL12) by glioma cells. CXCL12
interacts with the chemokine receptor CXCR4 on HPC.
Further, matrix metalloproteinase 9 cleaves and thereby
releases soluble Kit ligand (sKitL), which interacts with the
receptor CD117 on HPC (Tabatabai et al., 2005). Cerebral
irradiation promotes the homing of HPC to the tumour
bulk and to tumour satellites in vivo. Supernatants of
irradiated or hypoxic glioma cells enhance HPC migration
in vitro due to a TGF-b-dependent, hypoxia-inducible
factor-1a (HIF-1a)-mediated induction of CXCL12 pro-
moter activity in glioma cells (Tabatabai et al., 2006).
CXCL12 is also an important mediator for the attraction of
mesenchymal stem cells to experimental gliomas (Nakamizo
et al., 2005). A systemic gradient of CXCL12 alone,
however, does not explain the glioma-mediated attraction
of intravenously injected HPC. Moreover, further insight
into the mechanism of the glioma tropism is required for
the design of a HPC-based cellular therapy that specifically
targets gliomas.
The regional expression of endothelial adhesion mole-
cules may contribute to the specificity of HPC homing
towards gliomas. Similarities in the trafficking and homing
of HPC and leucocytes to particular tissue sites arise. The
diapedesis of leucocytes to sites of infection and inflamma-
tion is an important step in their recruitment. This process
ensures appropriate innate and adaptive immunological
responses. Adhesion molecules mediate rolling and arrest of
leucocytes on the vessel wall as key steps prior to the
transmigration across the endothelial layer (Millan et al.,
2006; Nieminen et al., 2006).
Adhesion is also critical for the interaction of HPC
within the haematopoietic microenvironment in the bone
marrow. Important mediators of this adhesive interaction
include vascular cell adhesion molecule 1 (VCAM-1),
platelet selectin (CD62P) and endothelial selectin (CD62E)
(Frenette et al., 1998; Katayama et al., 2003). CD62P is
deposited in storage granules of platelets and endothelial
cells. After activation, it is translocated to the surface
(Bevilacqua et al., 1989). VCAM-1 and CD62E are solely
expressed on endothelial cells (Mazo et al., 1998). In this
study, we analysed the role of HPC adhesion to endothelial
cells in the glioma tropism of HPC.
Material and Methods
Cell culture
Human adult HPC were isolated by anti-CD34 immunomagnetic
microbeads (Bautz et al., 2001). After informed consent,
peripheral blood cells were obtained from healthy donors or
patients with non-haematological malignancies during G-CSF-
induced stem cell mobilization, according to the guidelines of the
ethics committee of the University of Tu¨bingen (project number
268/2003-LP). The human CD34 antigen is a reliable marker for
identifying a small fraction of human bone marrow and peripheral
blood mononuclear cells consisting of primitive uncommitted and
pluripotent haematopoietic progenitor cells as well as haemato-
poietic stem cells (Andrews et al., 1986; Berenson et al., 1988;
Terstappen et al., 1991; Van Epps et al., 1994; Gothot et al., 1998;
Gao et al., 2001; Albo et al., 2004). The source, generation and
culture conditions of the cerebral vascular endothelial cell line SV-
HCEC and the astrocytic cell line SV-FHAS have been described
(Muruganandam et al., 1997). Brain tumour endothelial cells
(BTEC) were isolated from freshly resected human glioblastomas
and characterized for their endothelial cell phenotype as described
(Miebach et al., 2006). Briefly, the tissue was minced, homo-
genized and digested enzymatically. The cells were separated by
percoll gradient centrifugation. CD31-positive cells were isolated
by magnetic beads (Dynal, Hamburg, Germany). Only passage 0–2
cells were used for the experiments. Human microvascular
endothelial cells (HMEC) were purchased from Cascade
Biologics (Invitrogen GmbH, Karlsruhe, Germany). All glioma
cell lines were kindly provided by Dr N. de Tribolet (Lausanne,
Switzerland). In contrast to other LN-229 sublines, LN-229 glioma
cells cultured in our laboratory exhibit wild-type p53 status
(Wischhusen et al., 2003) and are designated LNT-229. The
generation of LNT-229 sublines stably depleted from TGF-b1 to
TGF-b2 by RNA interference (LNT-229 siTGF-b1,2) and the
control cells (LNT-229 puro) has been described (Friese et al.,
2004). The following primary glioma cultures were used: T113,
T159, derived from glioblastomas and T132, derived from an
anaplastic astrocytoma. The primary human glioma cultures were
established from samples with high tumour content (Ba¨hr et al.,
2003). Supernatants of glioma cells (SN-G) were generated in
serum-free medium (SFM): 1.5 million glioma cells were first
seeded in serum-containing medium in T75 cell culture flasks. The
medium was removed on the following day and the cells were
washed three times with PBS. Seven millilitres SFM were added,
48 h later, supernatants were harvested. Supernatant was concen-
trated using a Centriplus centrifugal filter device YM-3 (3 kD cut-
off, Millipore, Eschborn, Germany). Protein quantification was
performed using the Bradford assay (BioRad, Munich, Germany).
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Treatment of endothelial cells with SN-G was performed for 6, 12,
24, 48 or 96 h. Incubation of cells in hypoxia was performed at
37C and 1% O2 for 6, 12, 24, 48 or 96 h (Wick et al., 2002a).
Cells were irradiated at 2 or 8 Gy g-cell, Nordion, Kanata, CA,
USA) and analysed at 6, 12, 24, 48 or 96 h thereafter (Wick et al.,
2002b). Recombinant TGF-b2 and vascular endothelial growth
factor (VEGF165), neutralizing antibodies to VEGF (clone 26503)
and VEGF-R2 (clone 89106) were purchased from R&D Systems
(Wiesbaden-Nordenstadt, Germany). SD-208 was provided by Scios
(Fremont, CA, USA) (Uhl et al., 2004). siRNA pools targeting
human TGF-b1, TGF-b2 or VEGF containing four selected siRNA
duplexes each with a modification pattern that addresses off-target
effects caused by both strands (ON-TARGETplus SMARTpool) and
the non-targeting control pool (ON-TARGETplus siCONTROL
Non-targeting Pool) were designed by and purchased from
Dharmacon (Lafayette, CO, USA). The pool of siRNA duplexes
targeting TGF-b1 had the following sense sequences: 50-AUUG
AGGGCUUUCGCCUUAUU-30, 50-CCGAGAAGCGGUACCUGA
AUU-30, 50-GCAGAGUACACACAGCAUAUU-30, 50-GTGACUAU
CCACCUGCAAGAUU-30. The siRNA duplexes targeting TGF-b2
had the following sense sequences: 50-GGAUUGAGCUAUAUCAG
AUUU-30, 50-CUGCGUGUCCCAAGAUUUAUU-30; 50-GAUGCG
GCCUAUUGCUUUAUU-30, 50-GAGCAUGCCCGUAUUUAUGU
U-30. The siRNA duplexes targeting VEGF had the following sense
sequences: 50-GCAGAAUCAUCACGAAGUG, 50-CAACAAAUGUG
AAUGCAGA, 50-GGAGUACCCUGAUGAGAUC, 50-GAUCAAAC
CUCACCAAGGC. Lipophilic transfection was performed with
Metafectene Pro (Biontex, Martinsried, Germany).
Transendothelial migration of HPC
Migration assays were performed in transwell plates (Costar,
Cambridge, MA, USA) of 6.5 mm diameter with 5 mm pore filters.
SV-HCEC, HMEC or BTEC were plated at 105 cells/transwell on
filters coated with fibronectin. Non-adherent cells were removed
after 24 h. The adherent cells were cultured for 48 h to obtain
confluent endothelial monolayers. Confluency of the endothelial
monolayers was confirmed by measuring permeability for albumin
(Mo¨hle et al., 1997,1998; Naiyer et al., 1999). The monolayers
were used unstimulated, stimulated with SN-G or after exposure
to irradiation or hypoxia. Prior to the migration experiment, the
monolayer was washed three times with PBS. The 105 CD34+ HPC
in 200 ml SFM were added to the upper compartment. SFM,
recombinant CXCL12 or SN-G were added to the lower
compartment. In neutralization experiments, the SV-HCEC were
pre-incubated for 4 h at 37C with a-CD62E (R&D, clone BBIG-
E4[5D11]) or a-VCAM-1 (R&D, clone BBIG-V1 [4B2]) or
appropriate control antibodies. Migration was assessed at 37C,
5% CO2 for 16 h. Cells that had migrated to the lower
compartment were quantified with the CyQuant Assay
(Invitrogen, Karlsruhe, Germany).
Reporter assays
For dual luciferase/renilla assays (Dyer et al., 2000) 200 ng of the
respective reporter constructs was cotransfected with 20 ng of
pRL-CMV. pGL3b.CD62E contains the full-length promoter of
CD62E (Nu¨bel et al., 2004). pNFkB-Luc contains a firefly
luciferase gene that is especially designed for the detection of
nuclear factor kappa B (NFkB) signal transduction pathway
activity. It contains four copies of the NFkB consensus sequence
fused to a TATA-like promoter region from the Herpes simplex
virus thymidine kinase promoter. The binding of endogenous
NFkB leads to induction of transcription and activation of the
reporter gene in the transfected cells indicating transcriptional
activity of NFkB. Ad-IkBM, containing the NFkB repressor, and
the control Ad-Mock were kindly provided by Dr P. A. Baker
(McGill University, Ottawa, Canada).
TransAMNFkB family
Nuclear extracts were prepared (Nuclear Extract Kit, Active Motif,
Rixensat, Belgium) from SV-HCEC, HMEC or BTEC. Raji
extracts, provided by the assay, served as positive control.
Nuclear extracts from NIH3T3 fibroblasts served as negative
control. The transcriptional activity of the NFkB family p50, p65,
p52, c-Rel and RelB was analysed by the transcripton factor assay
TransAM NFkB family (Active Motif) according to manufacturer’s
protocol. Briefly, this assay is based on an enzyme-linked immu-
nosorbent assay (ELISA) format using 96-well plates coated with
immobilized oligonucleotides containing the NFkB consensus site.
The active form of NFkB contained in nuclear extracts of cells binds
to the oligonucleotides. Primary antibodies recognizing epitopes on
activated p50, p52, p65, c-Rel or RelB and HRP-conjugated
secondary antibodies are used for the detection and quantification
of active NFkB family members by spectrophotometry.
Immunoblot
Immunoblots were performed as described (Tabatabai et al.,
2006). The following antibodies were used: phospho-Smad 2 (Ser
465/467), total Smad 2 (Cell Signaling, Boston, MA, USA), NFkB
p50 and p65 (Santa Cruz, CA, USA) and GAPDH (Chemicon,
Billerica, MA, USA).
Enzyme-linked immunosorbent assay
The concentrations of VEGF, sCD62E, TGF-b1 and TGF-b2 in the
supernatants were determined by Quantikine Immunoassays from
R&D Systems. A sandwich ELISA was performed to measure the
levels of phosphorylated VEGF-R2 and total VEGF-R2 in cell
lysates (Duo Set IC, R&D Systems). The proliferation of cells was
assessed by a cell proliferation biotrak ELISA system (GE
Healthcare, Buckinghamshire, UK).
Flow cytometry
SV-HCEC, HMEC or BTEC were grown in 12-well plates either
untreated or stimulated with the indicated supernatant, hypoxia or
irradiation for 6, 12, 24, 48 or 96 h. Flow cytometry was performed
with a FACScalibur flow cytometer (Becton Dickinson, Heidelberg,
Germany) (Eisele et al., 2006). The following antibodies (R&D
Systems) were used: anti-human CD62E, VEGF-R2 and VCAM-1.
Signal intensity was calculated by dividing mean fluorescence
obtained with specific antibody divided by signal intensity obtained
with the isotype control antibody (specific fluorescence index, SFI).
Human tissue samples and tissue microarray
We investigated 120 glioblastoma samples (WHO grade IV)
obtained from the tumour bank of the Institute of Neuropathol-
ogy, University of Tuebingen derived from patients who under-
went surgical treatment from 1993 to 2003 at the Department of
Neurosurgery in Tuebingen or in the Department of Neurosurgery
in Seesen. Diffuse astrocytomas WHO grade II (n = 10) and
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anaplastic astrocytomas WHO grade III (n = 10) were also
investigated. All samples from diffuse and anaplastic astrocytomas
were taken from primary tumours prior to therapy. Among 120
glioblastoma samples, 88 were derived from primary and 32 from
recurrent tumours. Shortly after surgical removal, all specimens
were fixed with 4% formalin (pH 7.4) and subsequently embedded
in paraffin followed by preparation as tissue microarray (Warth
et al., 2007). Further, 60 samples from 33 autopsy cases of a
normal brain bank were added. Clinical data are summarized in
Table 1. The tumour and normal brain tissues were stained with
H&E, mouse anti-human antibodies to CD31 (Clone JC70A, Dako
Cytomation, Glostrup, Denmark, 51 mg/ml), goat anti-human
CD62E antibodies (Clone BBA18, R&D Systems, diluted 1:50) or
the respective isotype control antibodies.
Animal studies
On day 0, 104 SMA-560 cells were stereotactically implanted into
the right striatum of VM/Dk mice. On day 7, LSK were isolated
from the bone marrow of VM/Dk mice as described (Tabatabai
et al., 2005). Briefly, femora and tibiae of VM/Dk mice were
flushed with 2% FCS-containing PBS, erythrocytes were lysed,
bone marrow cells were incubated for 60 min at 4C with the
lineage marker antibodies rat anti-mouse CD4, CD8a, CD45R/
B220, Gr-1, CD11b and TER119 (BD Biosciences Pharmingen,
San Diego, CA, USA), then washed with PBS prior to the addition
of pre-washed sheep anti-rat IgG magnetic beads (Dynabeads,
Dynal, Biotech ASA, Oslo, Norway) at a 4 : 1 ratio of beads/cells.
After 45 min, beads and attached cells were magnetically removed.
The remaining lineage-depleted (lin–) cells were sorted with anti-
Sca1+ beads by MACS (Miltenyi Biotech, Bergisch Gladbach,
Germany). The check of purity by flow cytometry revealed that
55% of the isolated LSK expressed CD4, CD8, CD11b, B220 or
Gr-1. LSK were between 95% and 98% positive for Sca1 and
499% positive for c-kit (BD Biosciences Pharmingen). The LSK
were cultured with murine IL-3 (20 ng/ml), IL-6 (50 ng/ml) and
SCF (50 ng/ml) (R&D Systems) over night. On day 8, neutralizing
rat anti-mouse CD62E (BD Bioscience, clone 10E9.6) or control
antibodies were bolus-injected intraperitoneally (200 ml) and
intravenously (5ml). Four hours later, PKH26 (Sigma-Aldrich,
Taufkirchen, Germany) stained LSK were injected intravenously.
On day 10, mice were sacrificed. From each experimental group,
three brains were analysed by flow cytometry and three brains by
histology. For flow cytometry, 5 mm3 of the tumour-bearing as
well as the contralateral hemisphere were dissociated in single cell
suspension. For histology, 8 mm cryostat sections were stained with
H&E and antibodies to vWF (Dako Cytomation) or CD62E (BD
Biosciences). Nuclei were counterstained with 40,6-diamidino-
2-phenylindole (Vectashield with DAPI, Vector Laboratories,
Axxora GmbH, Loerrach, Germany).
Statistical analysis
Quantitative data were obtained for migration, ELISA, flow
cytometry and reporter assays as indicated. Data are expressed
as mean and SEM. Statistical significance was assessed by one-way
ANOVA followed by Tukey’s post hoc test (Excel, Microsoft,
Seattle, WA, USA). The experiments reported here were per-
formed at least three times in triplicate with similar results.
Results
Transendothelial HPCmigration is
enhanced after pretreatment of
endothelial cells with SN-G
The molecular signature of endothelial cells depends on the
environment. Endothelial cells from vessels within normal
tissue are different from endothelial cells of vessels within
inflamed or neoplastic tissue (Frenette et al., 1996b). To
simulate the conditioning of endothelial cells of vessels
within glioblastoma tissue in vitro, we cultured cerebral
endothelial cells (SV-HCEC) or HMEC in supernatant of
LNT-229, LN-308, T113, T159 or T132 glioma cells.
Further, we used BTEC from human glioblastoma speci-
mens. HPC migrated through an untreated SV-HCEC-,
HMEC (data not shown) and BTEC layer (Fig. 1). The
migration was significantly enhanced after the pre-
incubation of all three types of endothelial cell layer with
different SN-G. Pretreatment of the SV-HCEC, HMEC
(data not shown) and BTEC with hypoxia and irradiation
also increased the migration of HPC. In contrast, incuba-
tion with supernatant of the astrocytic cell line SV-FHAS
(SN-FHAS) did not modulate transendothelial migration.
Thus, SN-G, hypoxia or irradiation alter the characteristics
of endothelial cells and hence promote the transendothelial
migration of HPC.
SN-G induces the expression of CD62E on
SV-HCEC and HMEC
To understand the increase in transendothelial HPC
migration, we performed flow cytometry for the detection
of VCAM-1 and CD62E on SV-HCEC, HMEC or BTEC
either un- or pretreated with SN-G, irradiation or hypoxia.
Untreated SV-HCEC, HMEC and BTEC constitutively
expressed VCAM-1 at SFI values of 1.8, 1.7 and 1.9. The
expression of VCAM-1 was not altered after pretreatment
of the endothelial cells with SN-G, irradiation or hypoxia
(data not shown). In contrast, CD62E was expressed on
untreated BTEC but not on untreated SV-HCEC or HMEC.
However, SN-G enhanced or induced the expression of
CD62E as did hypoxia or irradiation (Fig. 2). Pretreatment
with VEGF165 served as a positive control.
Table 1 Clinical data
Origin of tissue Number Median age
(range) [years]
Female Male
Normal brain 33 brains 50.3 15 18
60 samples (22^77)
Diffuse astrocytoma 10 tumours 39.4 3 7
WHO grade II 10 samples (5^72)
Anaplastic astrocytoma
WHO grade III
10 tumours 44.7 ^ 10
10 samples (12^67)
Glioblastoma 88 tumours 58.1 35 53
WHO grade IV 120 samples (23^88)
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Endothelial cells of tumour vessels in human
astrocytomas but not normal brain vessels
highly express CD62E
To confirm the relevance of CD62E induction on endothelial
cells in vitro, we performed immunohistochemistry on
human tissue microarray sampling normal brain sections,
diffuse astrocytomas (WHO grade II), anaplastic astrocyto-
mas (WHO grade III) and glioblastomas (WHO grade IV).
Normal brain tissue contains small capillaries and vessels
whereas the vessels in glioblastomas are characteristically
composed of enlarged and thickened endothelial cell layers.
CD31 staining labelled endothelial cells within the vessel
walls of normal and neoplastic tissue. CD62E immunor-
eactivity was absent on endothelial cells of blood vessels
within normal human brain samples. In contrast, CD62E
was present in all neoplastic samples. CD62E strongly
correlated with blood vessel morphology. Large vascular
proliferations in glioblastoma samples showed the strongest
CD62E immunoreactivity whereas smaller, more regular
blood vessels found in the same tumours displayed a
weaker CD62E staining intensity (Fig. 3). There was no
difference between CD62E expression in samples derived
from primary or recurrent glioblastomas. A slight cyto-
plasmic CD62E staining was detected in tumour cells of
most tumour samples. This prompted us to determine the
concentration of soluble CD62E (sCD62E) in SN-G and in
supernatants of endothelial cells in vitro by ELISA.
Supernatant of BTEC harvested after 96 h contained
sCD62E (70 10 pg/ml) whereas SN-G and supernatant of
untreated SV-HCEC and HMEC did not. In contrast, 96 h
after stimulating SV-HCEC and HMEC with SN-G, sCD62E
was detected in the supernatant of these endothelial cells
(50–70 pg/ml). Thus, CD62E shedding and release of
sCD62E may account for the apparent cytoplasmic staining
observed in astrocytoma samples (Fig. 3).
Enhanced migration of HPC
through an SV-HCEC layer in vitro
depends on CD62E
We next investigated the role of HPC adhesion to CD62E
for transendothelial HPC migration through an SN-
G-conditioned endothelial cell layer. We studied the trans-
endothelial migration in the absence or presence of
neutralizing antibodies to CD62E either with or without
pretreatment of the endothelial cell layer. Neutralizing CD62E
reduced the transendothelial HPC migration significantly
(Fig. 4A, first panel). Because of the important regulatory
role of TGF-b for HPC glioma tropism (Tabatabai et al.,
2006), we also investigated the role of TGF-b in the
transendothelial HPC migration by targeting TGF-b expres-
sion and TGF-b signalling in glioma cells. We used stably
transfected LNT-229 siTGF-b1,2 cells (Friese et al., 2004;
Eisele et al., 2006) or siRNA pools targeting TGF-b1 and
TGF-b2, respectively, for transient transfection of LN-308
before collection of SN-G.
Transendothelial HPC migration through cells that had
been pretreated with supernatant of LNT-229 siTGF-b1,2
(SN-GsiTGF-b), was reduced and neutralizing a-CD62E did
not modulate HPC migration (Fig. 4A, second panel).
Further, transient transfection of LN-308 glioma cells with
siRNA pools targeting TGF-b1 and TGF-b2 inhibited
TGF-b1 and TGF-b2 release into the supernatant
(Fig. 4B). Combined targeting of TGF-b1 and TGF-b2 in
Fig. 1 Transendothelialmigration ofHPC through an SV-HCEC and
BTEC layer. SV-HCECor BTEC, either untreated or pretreatedwith
SN-G, hypoxia at1%O2 for 24h or irradiation at 2 and 8Gy,
were seeded on the transwells of a chemotaxis chamber.HPC
(105)were added to theupper chamber. SFM,CXCL12 or
supernatantof LNT-229were added to the lower compartment.
HPCmigrationwas assessed16h later.Thebars indicatemean
HPCmigration relative tomigration towards SFM through an
untreated SV-HCEC layer and SEM (n=3, #P50.05 compared
withuntreated SV-HCEC layer/SFMbottomwell; P50.05
comparedwithuntreated SV-HCEC layer/CXCL12 bottomwell;
P50.05 comparedwithuntreated BTEC layer/CXCL12 in
bottomwell).
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LN-308 cells inhibited the phosphorylation of Smad2
(Fig. 4B) indicating abrogation of TGF-b signalling. HPC
migration through endothelial cells that had been pre-
treated with supernatant of these cells was accordingly
reduced and neutralizing CD62E did not modulate the
migration (Fig. 4A, third and fourth panel).
Pre-irradiation of the endothelial cells resulted in an
enhancement of transendothelial HPC migration (Fig. 1)
that was also reduced by neutralizing CD62E antibodies
(Fig. 4C). In contrast, neutralizing VCAM-1 antibodies did
not significantly reduce HPC migration through an
untreated SV-HCEC- or BTEC or an SN-G-treated SV-
HCEC layer (Table 2). Exposure to hypoxia, irradiation,
supernatant, neutralizing or control antibodies did not
affect viability or proliferation of the endothelial cells or
glioma cells (data not shown).
Homing of murine HPC to orthotopically
implanted SMA-560 gliomas in vivo is
reduced after neutralization of CD62E
Subsequently, we investigated the role of CD62E for the
glioma tropism of murine HPC in an orthotopic syngeneic
glioma model in vivo. The 104 SMA-560 glioma cells were
implanted into the right striatum of VM/Dk mice. On day
8, 106 PKH26-stained LSK cells were injected intravenously.
Four hours before and 4 h after the injection of LSK,
CD62E-neutralizing antibodies (six mice) or control
Fig. 2 Flow cytometry demonstrates modulation of endothelial CD62E expression by SN-G, hypoxia or irradiation. CD62E expression
was analysed on the surface of endothelial cells without treatment, after stimulation with supernatant of LNT-229 for 48h,1% O2 for 24h,
24h after irradiation at 2 and 8Gy or exposure to VEGF165 (40ng/ml) for 24h.
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antibodies (six mice) were bolus-injected both intraperito-
neally and intratumourally in parallel in the same animals
to block adhesion. On day 10, the brains were removed.
Three brains per group were used for assessment by flow
cytometry, three brains were analysed by histology. Injection
of CD62E and control antibodies did not affect tumour
morphology, tumour growth or vessel density as assessed by
H&E or vWF staining (Fig. 5A). The endothelial cells of
tumour vessels expressed CD62E (Fig. 5A). Fluorescence
staining showed reduced numbers of PKH26-labelled cells
within the SMA-560 gliomas after pretreatment with anti-
CD62E antibodies (Fig. 5B). Single cell suspensions of freshly
removed samples of the SMA-560 gliomas or of the
contralateral hemisphere were analysed by flow cytometry
to quantify the numbers of PKH26-labelled cells.
Co-treatment with anti-CD62E antibody strongly reduced
the amount of PKH26-positive LSK in orthotopic SMA-560
gliomas (Fig. 5C).
TGF-b signalling in glioma cells is required
for SN-G-mediated induction of CD62E
expression on SV-HCEC
We then characterized the time course of CD62E induction
in SV-HCEC and HMEC. TNF-a treatment (100 U/ml)
served as a positive control. This treatment resulted in high
expression of CD62E by SV-HCEC (Fig. 6A) and HMEC
(Fig. 6B) after 6 h, then declining over the next 90 h.
Similarly, treatment with VEGF165 (40 ng/ml) resulted in
high CD62E expression after 6 h, which was no more
detectable 96 h after treatment. Culturing of SV-HCEC or
HMEC in supernatant of the astrocytic cell line SV-FHAS
did not induce CD62E expression. Treatment of SV-HCEC
or HMEC with SN-G resulted in a maximum CD62E
expression at 12 h (Fig. 6A and B).
Next, we analysed the role of TGF-b signalling for the
induction of CD62E. The treatment of SV-HCEC with
recombinant TGF-b2 (10 ng/ml) did not induce CD62E
expression (Fig. 7A). We also collected supernatant of
glioma cells that had been pretreated with the TGF-b
receptor I kinase inhibitor, SD-208 (0.1mmol/l and
1.0 mmol/l). SD-208 treatment blocked TGF-b signalling in
LN-308, T113 and T132 cells (Fig. 7B). The exposure of
SV-HCEC to supernatant of these SD-208-treated glioma
cells did not induce CD62E expression (Fig. 7A). In
accordance, exposure of SV-HCEC to SN-308 siTGF-b1,2
(Fig. 4A and B) did not induce CD62E (Fig. 7A). Finally,
we also treated LNT-229 siTGF-b1,2 cells stably depleted
from TGF-b1 and TGF-b2 (Friese et al., 2004) with
recombinant TGF-b2 (10 ng/ml) for 7 days to rescue
TGF-b signalling in these glioma cells (Friese et al., 2004;
Tabatabai et al., 2005; Eisele et al., 2006). Supernatant from
these cells again induced CD62E on SV-HCEC (Fig. 7A). In
contrast, the treatment of SV-HCEC with SN-G in the
presence of SD-208, which abrogates TGF-b signalling
pathway in SV-HCEC and HMEC (Fig. 7C), did not
influence the SN-G-mediated induction of CD62E. The
exposure of endothelial cells to SN-GRT or SN-GHO led to
the induction of CD62E, too. This effect was again
prevented by SD-208 treatment of the glioma cells before
harvesting the supernatant (data not shown).
The experiments involving the addition of recombinant
TGF-b2 or SD-208 indicate that (i) TGF-b signalling in
glioma cells is required for the induction of CD62E on
endothelial cells; but (ii) TGF-b signalling in SV-HCEC is
Fig. 3 Endothelial cells of human astrocytoma vessels
highly express CD62E. Representative samples of normal
brain tissue, diffuse astrocytoma (WHO grade II), anaplastic
astrocytoma (WHO grade III) and glioblastoma are shown.
CD31 staining was used to detect the vessels within the normal
brain or the tumour tissue. Depicted are H&E staining, immuno-
reactivity for CD31 and CD62E and the isotype control for CD62E
(size bar bottom left: 50mm).
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Fig. 4 Neutralizing CD62E antibodies diminish transendothelial HPC migration in vitro. (A) HPC migration through SV-HCEC layer treated
with SN-Gp-, SN-GsiTGF-b-, supernatant of LN-308 co or siTGF-b1,2 towards CXCL12 in the bottom well after addition of neutralizing
CD62E antibodies (grey bars) or of the respective IgG isotype control (black bars) was assessed (P50.05 compared with IgG; +P50.05
compared with SN-Gp; #P50.05 compared with supernatant of LN-308 co; co=non-targeting control siRNA pool). (B) Immunoblot for
detection of phospho Smad2, total Smad2 and GAPDH loading control; ELISA detectingTGF-b1 orTGF-b2 levels (NT=not treated,
co=non-targeting control siRNA pool, 1= transfected with siRNA pool targetingTGF-b1, 2= transfected with siRNA pool targetingTGF-
b2, 1&2=co-transfection with siRNA pools targetingTGF-b1 and TGF-b2). (C) HMEC or BTECwere untreated or irradiated. HPC migra-
tion was assessed after the addition of neutralizing CD62E antibodies (grey bars) or the corresponding IgG isotype control (black bars)
(P50.05 compared with IgG).
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not involved in SN-G-mediated induction of CD62E
expression.
Induced CD62E expression on SV-HCEC is
mediated by VEGF-R2 signalling
We next analysed the levels of VEGF, a candidate inducer of
CD62E expression, in concentrated SN-Gp and SN-GsiTGF-b
from cells treated with or without SD-208 or TGF-b2
(Table 3). VEGF release was reduced by abrogated TGF-b
signalling. In contrast, addition of recombinant TGF-b2 to
LNT-229 siTGF-b1,2 cells for 7 days before generation of
supernatant restored VEGF levels in the supernatant. Further,
irradiated and hypoxic SV-HCEC released increased levels of
VEGF (Table 3). SV-HCEC, HMEC and BTEC expressed
the corresponding receptor VEGF-R2 (Fig. 8A). Therefore,
we analysed the role of VEGF/VEG-R2 signalling in
endothelial cells for CD62E induction. Treatment of SV-
HCEC, HMEC or BTEC with VEGF165, SN-G, hypoxia or
irradiation increased the levels of phosphorylated VEGF-R2.
NIH3T3 cells were used as negative controls (Fig. 8B). The
levels of total VEGF-R2 in untreated SV-HCEC (597 pg/ml)
did not increase by exposure of SV-HCEC to VEGF165
(590 pg/ml) or supernatant of LN-308 (572 pg/ml).
Pretreatment with hypoxia, 2 Gy or 8 Gy, however, increased
the levels of total VEGF-R2 in SV-HCEC (807, 992 and
2670 pg/ml). Similarly, the levels of total VEGF-R2 in
untreated HMEC (664 pg/ml) was not increased by exposure
to VEGF165 (579 pg/ml), supernatant of LN-308 (660 pg/ml),
whereas hypoxia (772 pg/ml), irradiation at 2 Gy (1222 pg/
ml) or 8 Gy (2982 pg/ml) led to elevated levels of total VEGF-
R2 protein in HMEC. In BTEC, we detected levels of total
VEGF-R2 in untreated (502 pg/ml), hypoxic (452 pg/ml) or
irradiated cells (2 Gy: 459, 8 Gy 449 pg/ml). These data
indicate that VEGF-R2 signalling activity in SV-HCEC,
HMEC and BTEC is enhanced in response to SN-G, hypoxia
or irradiation. Targeting of VEGF in glioma cells by siRNA
pools led to a reduced VEGF release by LN-308 glioma cells or
T113 primary cultures (Fig. 8C). VEGF levels were also are
reduced in supernatant of LN-308 siTGF-b1,2 (Fig. 8C) and
supernatant of LNT-229 after inhibition of TGF-b signalling
(Table 3). The SN-G-mediated de novo expression of CD62E
was prevented by VEGF gene silencing and by neutralizing
VEGF or VEGF-R2 antibodies (Fig. 8D). Further, the
exposure of SV-HCEC to irradiation or SN-G, SN-GRT or
SN-GHO supplemented with neutralizing a-VEGF and
a-VEGF-R2 antibodies prevented CD62E induction (data
not shown). Thus, (i) SN-G enhances VEGF-R2 signalling
activity in endothelial cells; (ii) VEGF from SN-G, SN-GHO
or SN-GRT is required for the SN-G-induced expression of
CD62E in SV-HCEC; (iii) VEGF release from SV-HCEC is
required for CD62E induction after exposure to hypoxia or
irradiation.
Transcriptional activation of CD62E in
endothelial cells is mediated by NFkB
The promoter of CD62E contains multiple NFkB-binding
sites (Schindler et al., 1994). We detected NFkB p65 and
p50 in whole cell lysates of SV-HCEC (Fig. 9A). Protein
levels were not modulated by irradiation, hypoxia or
exposure to SN-Gp, SN-GsiTGF-b or SN-GRT. Futher, we
analysed the activation of the NFkB transcription family in
nuclear extracts of BTEC, SV-HCEC and HMEC (Fig. 9B).
Raji extracts served as positive control, nuclear extracts
from NIH3T3 cells were used as negative controls. The
NFkB transcription factor family is activated in untreated
endothelial cells. We next analysed the activity of p50 in
nuclear extracts of endothelial cells after treatment with
VEGF165 or SN-G. TNF-a served as positive control
(Fig. 9C). VEGF165 and SN-G further increased the tran-
scriptional activity of p50 whereas treatment with super-
natant of LN-308 siVEGF did not. In addition, we
performed reporter assays with pNFkB-luc. This plasmid
contains four copies of the NFkB consensus sequence
and detects the transcriptional activity of NFkB. Treatment
with TNF-a (100 U/ml) served as a positive control (Figs 9
and 10). The relative luciferase activity of pNFkB-luc in
untreated BTEC, SV-HCEC and HMEC demonstrates the
baseline transcriptional activity (Fig. 9D) in accordance
with the data of the transAM assay (Fig. 9B and C).
Table 2 Transendothelial HPC migration: no modulation
by VCAM antibodies
Treatment of monolayer Chemoattractant HPC migration
[fold increase]
SV-HCEC, untreated SFM 1
CXCL12 3.1
SN-G 7.1
SV-HCEC, a-VCAM-1 SFM 1
CXCL12 3
SN-G 6.9
SV-HCEC, SN-G SFM 1.6
CXCL12 6.5
SN-G 11.6
SV-HCEC, SN-G+a-VCAM-1 SFM 1.2
CXCL12 6.1
SN-G 11.3
BTEC, untreated SFM 1
CXCL12 8
SN-G 8.5
BTEC, a-VCAM-1 SFM 1
CXCL12 7.5
SN-G 8
CD34+ HPC (105) were added to the upper compartment of an
endothelial cell monolayer-covered transwell insert. The mono-
layer was either untreated or stimulated with SN-G. SFM,CXCL12
(100ng/ml) or supernatant of LNT-229 cells were added to the
bottom wells. Relative transendothelial migration, i.e. migration
related to basal migration towards SFM through the untreated
monolayer, was determined 16h later with or without neutralizing
a-VCAM1-antibodies (mean, n=3, SEM510%).
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After exposure to TNF-a, VEGF165 or SN-G, NFkB
transcriptional activity significantly increased. Neutralizing
antibodies to VEGF and VEGF-R2 reduced SN-G-induced
NFkB transcriptional activity (Fig. 10).
In parallel, we analysed the activity of the CD62E pro-
moter by measuring the relative luciferase activity of
pGL3basic.CD62E. In this plasmid, the reporter gene is
driven by the CD62E promoter and indicates the activity of
Fig. 5 Neutralizing CD62E antibodies diminish the attraction of murine HPC by orthotopic SMA-560 gliomas in vivo. (A) Morphology of
SMA-560 glioma was assessed by H&E. vWF and CD62E proteins were visualized by immunohistochemistry. CD62E is expressed by
tumour endothelial cells. Isotype controls for vWF and CD62E are displayed as inserts. H&E and corresponding vWF and CD62E stainings
of one mouse per experimental group are displayed. Size bar bottom left: 100mm. (B) Fluorescence microscopy after nuclear counter-
staining with DAPI for the detection of glioma cells (blue) and PKH26 stained LSK (red). Size bars bottom left: 100mm and bottom right:
50mm. (C) The numbers of PKH26-stained LSK in the SMA-560 gliomas or in the contralateral hemisphere (NB) were quantified by flow
cytometry. In (A), (B), (C), a-CD62E=treatment with neutralizing CD62E antibodies, IgG=treatment with control antibodies.
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the CD62E promoter. We detected relative luciferase activ-
ity in untreated BTEC indicating a baseline promoter
activity in accordance with the data from flow cytometry
(Fig. 2). In contrast, luciferase activity was absent in
untreated SV-HCEC or HMEC, indicating a lack of CD62E
promoter activity in this cell population (Fig. 9D). After
treatment with TNF-a, VEGF165 or SN-G, however, the
relative luciferase activity of pGL3.basic.CD62E increased
(Fig. 10). Irradiation with 2 Gy, 8 Gy or hypoxia also
increased pGL3.basic.CD62E activity (data not shown).
NFkB transcriptional activity and CD62E promoter activity
were reduced by neutralizing a-VEGF and a-VEGF-R2
antibodies (Fig. 10). To analyse whether NFkB transcrip-
tional activity is required for CD62E promoter activity, we
performed reporter assays after targeting NFkB by the
NFkB-super-repressor Ad-IKBM. We transduced SV-HCEC
with 100 MOI of Ad-IKBM. Ad-Mock served as control.
Relative luciferase activity of pGL3.basic.CD62E in
SV-HCEC was not induced by SN-G in the presence of
the NFkB super repressor (Fig. 10). These experiments
place VEGF signalling and NFkB upstream of the
transcriptional activation of CD62E in SV-HCEC. The
presumptive signalling cascade leading to the induction of
CD62E in SV-HCEC by SN-G, irradiation or hypoxia is
summarized in Fig. 11.
Discussion
Adult HPC migrate towards experimental gliomas.
Therefore, this adult stem cell population might be a
promising cellular vector for the delivery of therapeutic
molecules to experimental gliomas. Before applying ther-
apeutic approaches, however, the underlying molecular
mechanisms of the glioma-mediated HPC attraction should
be better understood. The objective in characterizing the
glioma tropism of HPC is to achieve an optimal seeding of
experimental gliomas with HPC. Adhesion molecules
expressed on endothelial cells serve as keys to allow the
entrance of circulating cells at specific tissue sites (Frenette
et al., 1996a). Bone marrow- and umbilical cord blood-
derived CD34+ HPC adhere to CD62E on bone marrow
microvasculature (Najyer et al., 1999; Dimitroff et al., 2001;
Hidalgo et al., 2002; Greenberg et al., 2000). P- and
E-selectin-deficient mice exhibit severe deficiencies in
haematopoiesis (Frenette et al., 1996). Intravital microscopy
studies show that P- and E-selectin contribute to HPC
rolling in the bone marrow microvasculature. Blocking both
selectins and VCAM-1 inhibits the rolling interaction
almost completely (Mazo et al., 1998). Hidalgo et al.
(2002) demonstrated by fluorescence intravital microscopy
and homing assays in NOD/SCID mice that endothelial
selectins are necessary for CD34+ HPC homing: rolling on
bone marrow endothelium and retention in the bone
marrow compartment are severely reduced in CD62E-
deficient NOD/SCID mice. Thus, homing of HPC to the
bone marrow is mediated by HPC interactions with
multiple adhesion receptors. Among these, CD62E and
VCAM-1 are expressed preferentially on endothelial cells.
Therefore, we focused on investigating the possible
contribution of CD62E and VCAM-1 to HPC glioma
tropism.
CD62E expression in glioma-conditioned
endothelial cells in vitro and in vivo
We used three different endothelial cell types: the cerebral
endothelial cell line SV-HCEC (Muruganandam et al.,
1997), the endothelial cell line HMEC and BTEC (Miebach
et al., 2006). These endothelial cells constitutively express
VCAM-1, but not CD62E. In the bone marrow micro-
vasculature, CD62E and VCAM-1 are constitutively expres-
sed (Schweitzer et al., 1996). In most other tissues, however,
CD62E is transcriptionally regulated and expressed on the
surface after exposure to specific inflammatory stimuli
(Bevilacqua et al., 1989). We found CD62E expression on
untreated BTEC. De novo CD62E expression by SV-HCEC
Fig. 6 Time-course of induced CD62E expression in SV-HCEC
and HMEC. Flow cytometry was performed to investigate CD62E
expression of SV-HCEC (A) or HMEC (B) at 6, 12, 24, 48 and 96h
after pretreatment as indicated. Note that an SFI of 1 indicates the
absence of protein expression.
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and HMEC was induced after stimulation with SN-G,
SN-GHO or SN-GRT, as well as treatment with hypoxia
(Fig. 2) or irradiation. The constitutive VCAM-1 expression
on the endothelial cells was not altered by these treatments.
These results differ from studies with bone marrow
microvasculature: total body irradiation of mice increased
VCAM-1 expression, but the constitutive expression level
of CD62E within the bone marrow microvasculature
was unchanged (Mazo et al., 2002). Having observed an
SN-G-induced CD62E expression by SV-HCEC and HMEC
in vitro, we analysed CD62E expression in situ. The
endothelium of vessels within astrocytoma tissue of WHO
grades II–IV highly expressed CD62E whereas CD62E
staining was absent in normal brain (Fig. 3). In addition
to the well-defined CD62E staining of tumour endothelium,
there was a diffuse extracellular and cytoplasmic staining in
the neoplastic specimens. This might indicate the shedding
of CD62E and the presence of the soluble form of CD62E
(Oh et al., 2007). In that regard, we also detected sCD62E
Fig. 7 The role of TGF-b signalling for the induction of CD62E expression. (A) Flow cytometry was performed to analyse CD62E
expression of SV-HCEC after the indicated treatments. (B) Immunoblot for the detection of phospho Smad2, total Smad2 and GAPDH in
lysates of LN-308, T113 orT132 after treatment with SD-208. (C) Immunoblot for the detection of phospho Smad2, total Smad2 and
GAPDH in lysates of SV-HCEC or HMEC after treatment with SD-208. In (B) and (C) NT=not treated,V=vehicle, 0.1=SD-208
0.1mmol/l, 1.0=SD-208 1.0mmol/l.
Table 3 Modulation of VEGF release by LNT-229 and
SV-HCEC
Concentrated Supernatants VEGF [pg/ml]
LNT-229 390
LNT-229 puro 410
LNT-229 puro, pretreated with DMSO 400
LNT-229 puro, pretreated with SD-208 85
LNT-229 siTGF-b1,2 94
LNT-229 siTGF-b1,2 treated with
recombinant TGF-b2
370
SV-HCEC 50
SV-HCEC, 1% O2, 12h 610
SV-HCEC, 1% O2, 24h 920
SV-HCEC, 2Gy 680
SV-HCEC, 8Gy 750
VEGF protein levels were determined in concentrated supernatant
by ELISA.The cells were either untreated, preincubated with
SD-208 (1mmol/l, 24h) or vehicle, TGF-b2 (10ng/ml, 7 days),
exposed to1% O2 for12h and 24h or preirradiated (2Gy, 8Gy, 48h
before harvest of supernatant) (mean, n=5, p50.01, SEM510%).
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in supernatant of stimulated SV-HCEC, HMEC and in
supernatant of untreated BTEC in vitro.
CD62E is one mediator of the
glioma-mediated HPC attraction
in vitro and in vivo
The transendothelial migration of HPC was significantly
diminished in the presence of neutralizing CD62E antibodies
(Fig. 4) whereas neutralizing VCAM-1 antibodies had no such
effect. In vivo, administration of a CD62E-blocking antibody
prevented the accumulation of PKH26-positive LSK in
orthotopic SMA-560 gliomas (Fig. 5), indicating that
CD62E is required for the glioma tropism of LSK in vivo. In
a model of chronic kidney disease, Gong et al. (2006)
demonstrated de novo CD62E expression in renal vascular
endothelium mediating leucocyte adhesion. The bolus
injection of neutralizing CD62E antibodies diminished
interstitial inflammation and macrophage sequestration in
the kidney in vivo. Recently, Nishiwaki et al. (2007)
demonstrated a crucial role for CD62E in the interaction
between circulating endothelial progenitor cells and vessel
Fig. 8 The role of VEGF/VEGF-R2 signalling for the induction of CD62E expression. (A) Flow cytometry was performed to determine
VEGF-R2 expression of SV-HCEC, HMEC and BTEC. (B) The levels of phosphorylated VEGF-R2 in SV-HCEC, HMEC, BTEC or NIH3T3
cells were asssessed after the indicated treatments. (C) ELISAwas performed to evaluate the release of VEGF after the indicated treat-
ments. (D) CD62E expression was analysed by flow cytometry after the indicated treatments.
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endothelium in the mouse hind-limb ischaemia paradigm.
Oh and colleagues (2007) demonstrated that CD62E is a
pivotal molecule for endothelial progenitor cell homing to the
ischaemic site and for vasculogenesis in an ischaemic limb
model. Based on these data, a novel cell-based therapy for
ischaemic atherosclerosis might be designed.
SN-G-mediated induction of CD62E
requiresTGF-b signalling in glioma cells
and VEGF/VEGF-R2 signalling in
endothelial cells
We next investigated the molecular mechanism mediating
the de novo expression of CD62E in SV-HCEC or HMEC.
Culturing of SV-HCEC with SN-GsiTGF-b did not induce
CD62E expression (Fig. 7). HPC migration through an SN-
GsiTGF-b-treated SV-HCEC layer was not altered by
neutralizing a-CD62E. The reduction of relative HPC
migration (Fig. 4A) observed after pretreating SV-HCEC
with SN-GsiTGF-b can be explained by the lack of CD62E
expression (Fig. 7). Based on this observation, we analysed
the role of TGF-b signalling in the glioma-mediated
induction of CD62E. When TGF-b signalling was inhibited
in LNT-229 glioma cells before supernatant collection—
either by SD-208 or by siRNA—these supernatants did not
induce CD62E expression (Fig. 7). Inhibition of TGF-b
signalling in SV-HCEC or HMEC by SD-208, however,
did not modulate SN-G-mediated CD62E induction.
Further, treatment of SV-HCEC with recombinant
Fig. 9 NFkB protein levels and transcriptional activity of NFkB
family members in endothelial cells. (A) Immunoblots show the
expression of NFkB in lysates of SV-HCEC either untreated or
after exposure to 1% O2, irradiation at 8Gy, treatment with
SN-GRT, SN-Gp or SN-GsiTGF-b. GAPH was used as a loading
control. (B) Profiling of the transcriptional activity of the NFkB
family in endothelial cells. (C) Transcriptional activity of p50 was
assessed in SV-HCEC or HMEC 24h after the indicated
treatments. (D) Untreated BTEC, SV-HCEC or HMECwere
transfected with NFkB-luc or pGL3b.CD62E.The bars indicate
relative luciferase activity.
Fig. 10 Transcriptional activation of CD62E by SN-G is mediated
by NFkB. SV-HCECwere transfected with NFkB-luc or
pGL3b.CD62E either alone or transduced with the NFkB
super repressor Ad-IKBM or Ad-Mock. The cells were then
treated withTNF-a,VEGF165 or supernatant as well as supernatant
with neutralizing VEGF or VEGF-R2 antibodies. The bars indicate
relative luciferase activity (n=3, P50.01 compared with
pGL3b.CD62E).
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TGF-b2 alone did not induce CD62E (Fig. 7). We
concluded that glioma-mediated CD62E induction requires
intact TGF-b signalling in the glioma cells, but not in SV-
HCEC. Inhibition of TGF-b signalling in glioma cells also
led to diminished VEGF levels (Table 3, Fig. 8C).
Irradiation with 2 or 8 Gy and pre-exposure to hypoxia
on the other hand increased VEGF secretion by SV-HCEC
and HMEC (Table 3). We therefore analysed the influence
of VEGF/VEGF-R2-signalling on CD62E induction in SV-
HCEC. Treatment of SV-HCEC and HMEC with super-
natant of glioma cells that had been transfected with siRNA
pools targeting VEGF did not induce CD62E (Fig. 8D).
Neutralization of VEGF or VEGF-R2 bioactivity impaired
SN-G-mediated CD62E induction (Fig. 8D) indicating a
pivotal role of this signalling pathway in SV-HCEC or
HMEC in the induction of CD62E expression. Recently,
Stannard et al. (2007) demonstrated that VEGF primes
endothelial cells by sensitizing them to cytokines, leading to
enhanced selective pro-inflammatory responses, including
upregulation of CD62E.
De novo expression of CD62E by endothelial
cells is mediated by NFkB
To further characterize the downstream events after VEGF-
R2 activation, we performed reporter assays. SN-G,
irradiation or hypoxia induced CD62E promoter activity
in SV-HCEC. Since the CD62E promoter contains three
NFkB binding sites (Schindler et al., 1994), we analysed the
role of NFkB in our paradigm. NFkB is expressed and
transcriptionally active in SV-HCEC, HMEC and BTEC
(Figs 9 and 10). NFkB is also activated in pre-sheared
HUVEC leading to NFkB-dependent cytoprotective respon-
siveness (Patridge et al., 2007). Consequently, we investi-
gated the upstream control of CD62E promoter activity
with the NFkB superrepressor, Ad-IkBM. Inhibition of
NFkB acitivity strongly reduced CD62E promoter activity
(Fig. 10). This central role of NFkB activity for CD62E
induction in our studies parallels results in other models:
endothelial cell activation by HIV infection results in
CD62E expression via a Tat-induced NFkB-mediated path-
way (Cota-Gomez et al., 2002). CD62E induction within an
atherosclerotic lesion is evoked by the platelet-specific
chemokine 4 derived from platelets and activation of
NFkB was crucial for CD62E induction on endothelium by
platelet-specific chemokine 4 (Yu et al., 2005).
In summary, we define a signalling cascade leading to
CD62E induction on endothelial cells in response to
treatment with SN-G, SN-GHO, SN-GRT, irradiation or
hypoxia. This cascade involves a TGF-b-dependent release
of VEGF by glioma cells and the subsequent activation of
VEGF-R2 in endothelial cells resulting in NFkB-mediated
CD62E expression. We observed a selective expression of
this adhesion molecule in human astrocytoma samples of
WHO grades II–IV and demonstrated the functional
relevance of CD62E for transendothelial HPC migration
in vitro and in vivo. Therefore, we conclude that adhesion
to CD62E on tumour endothelium might be a pivotal first
step in the glioma tropism of HPC. Given the central role
of VEGF in the glioma-mediated induction of CD62E on
endothelial cells, a putative HPC-based therapy against
glioblastomas might not be effective in combination with
antiangiogenic strategies targeting VEGF, e.g. enzastaurin or
bevacizumab.
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